CME: Charting the course to best practice in the recognition and management of amyotrophic lateral sclerosis (ALS)
ACCREDITATION EXPIRED: February 06, 2026
Activity Description / Statement of Need:
In this online, self-learning activity:
Amyotrophic lateral sclerosis (ALS), characterized by loss of motor neurons in the cortex and spinal cord and progressive paralysis. A quarter of patients survive no more than six months after symptom onset or diagnosis, and the majority of patients die from respiratory failure within 5 years. Although the etiology of ALS remains unknown, evidence suggests autoimmune mechanisms, genetic mutations, and environmental factors play roles. Occurring more commonly in men, the incidence of ALS varies widely and is estimated to be between 1 and 23 per 100,000 person-years, and the prevalence 6 to 9. Estimates of the economic burden range from $64,000 to $200,000 per patient per year.
Target Audience:
The following HCPs: neurologists, physician assistants, nurse practitioners, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with ALS.
Commercial Support Disclosure: This program is supported by an educational grant from Mitsubishi Tanabe.
This activity is free of charge.
Release Date: February 06, 2024 -- Expiration Date: February 06, 2026
Faculty: Jeffrey A. Mullen, MD
Agenda
|
Faculty introduction, disclosures |
|
Introductory content · Epidemiology · Pathophysiology, clinical features, risk factors, biomarkers, and diagnosis (including differential diagnosis)
|
|
Managing amyotrophic lateral sclerosis
· Glutamatergic inhibition · Free radical-directed therapy · Histone deacetylase inhibition · Antisense oligonucleotide therapy · Role and importance of supportive therapies: respiratory, nutrition, musculoskeletal, pain-related, and psychological
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the healthcare burden unique to patients with ALS and challenges to optimal identification and management.
- Identify current and emerging treatment strategies and their present or anticipated places in therapy for ALS.
- Formulate a treatment plan for a patient with ALS.
Accreditation
ACCME Activity #202607834
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Jeffrey A. Mullen, MD, Assistant Professor, Department of Neurology, UCI School of Medicine, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Mitsubishi Tanabe.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.